Sanofi Debt to Equity Ratio
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SNY Debt to Equity Ratio Range, Past 5 Years
| Minimum | 0.06 | Dec 2003 |
| Maximum | 2.46 | Jun 2006 |
| Average |
About Debt to Equity Ratio
YCharts Calculation: Debt to Equity = (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity
The debt to equity ratio is a leverage ratio indicating the relative proportion of shareholders' equity and debt used to finance a company's assets. It reveals how a company has financed its assets. A low debt to equity ratio indicates lower risk because shareholder's have claims on a larger portion of the company's assets.
A high debt to equity ratio usually means that a company has been aggressive in financing growth with debt and often results in volatile earnings.
It is also known as Debt/Equity Ratio, Debt-Equity Ratio, and D/E Ratio.
Learn More
You may also be interested in these SNY related companies
SNY News
Sanofi's (SNY) Genzyme Reports Continued Endpoint Improvement for Eliglustat Tartrate in Phase 2 Trials
Feb 08, 11:04AM Street Insider
Feb 08, 11:04AM Street Insider
Sanofi (SNY), Bristol-Myers Squibb (BMY) Get $442.2M Payment from Plavix Settlement
Feb 08, 6:52AM Street Insider
Feb 08, 6:52AM Street Insider
Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex
Feb 08, 1:30AM Business Wire
Feb 08, 1:30AM Business Wire
Sanofi Announces FDA Approval of Sklice® Lotion for the Treatment of Head Lice
Feb 07, 2:05PM Benzinga
Feb 07, 2:05PM Benzinga
A Forward Look, the Year Ahead - Featured Research on Sanofi SA (ADR) and Endo Pharmaceuticals
Feb 06, 9:00AM Marketwire
Feb 06, 9:00AM Marketwire
R&D in Quebec pharma industry continues to erode $AZN $JNJ $SNY $MRK
about 10 days ago by michaelbabad
about 10 days ago by michaelbabad
$SNY informs $REGN of voluntary withdrawl of Zaltrap BLA based on FDA comments. Plans to resubmit in early 2012 http://stks.co/1eBM
about 53 days ago by TradeHawk
about 53 days ago by TradeHawk
Looking for Euro denominated share ADRs with large US revenues. e.g., $SNY, $SI. Suggestions?
about 59 days ago by paladinmoney
about 59 days ago by paladinmoney
I have to say, it really is ironic that $SNY has one of the lowest valuations in big-pharma when it has the best management by far.
about 63 days ago by bradloncar
about 63 days ago by bradloncar
Business Insider - Barron's: Here Are The Top 10 Stocks For 2012 $BRKA $MET $SNY $STX $FCX $CMCSA $RDSA $PG http://stks.co/1TzI > buy puts?
about 64 days ago by OptionsCommander
about 64 days ago by OptionsCommander
I detail everything that goes into my Risk/Reward scoring system in my book, Better Good than Lucky. http://stks.co/1Tqp $RDS.A $SNY $VOD
about 65 days ago by charlesrotblut
about 65 days ago by charlesrotblut
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SNY | 37.23 | -0.18 | -0.48% | 97.62B |
| DIT | 65.30 | 0.03 | 0.04% | 40.48M |
| XIN | 2.36 | -0.08 | -3.28% | 180.54M |
| FRP | 4.42 | -0.43 | -8.87% | |
| GCI | 14.61 | -0.42 | -2.79% | 3.48B |
| AGM | 20.40 | -0.54 | -2.58% | 211.14M |
| APC | 87.04 | -0.42 | -0.48% | 43.34B |
| GNW | 8.73 | -0.17 | -1.96% | 4.29B |
| RKT | 68.04 | 0.53 | 0.79% | 4.80B |
| UNP | 111.63 | -1.17 | -1.04% | 53.93B |
